Iain Dukes's Insider Trades & SAST Disclosures
Iain Dukes's most recent trade in Iovance Biotherapeutics Inc was a trade of 98,607 Deferred Restricted Stock Unit done . Disclosure was reported to the exchange on June 11, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Iain Dukes.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics Inc | Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 98,607 | 98,607 | - | - | Deferred Restricted Stock Unit | |
| Ikena Oncology Inc | Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 17,520 | 17,520 | - | - | Stock Option (Right to Buy) | |
| Traws Pharma Inc. | Iain D. Dukes | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 3,802,890 | 3,802,890 | - | - | Stock Option (right to purchase) | |
| Traws Pharma Inc. | Iain D. Dukes | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 1,645,100 | 1,645,100 (1%) | 1% | - | Common Stock | |
| Traws Pharma Inc. | Iain D. Dukes | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 67,550 | 134,187 (0%) | 0% | - | Common Stock | |
| Traws Pharma Inc. | Iain D. Dukes | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 67,500 | 134,187 (0%) | 0% | - | Common Stock | |
| Traws Pharma Inc. | Iain D. Dukes | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 66,687 | 66,687 (0%) | 0% | - | Common Stock | |
| Traws Pharma Inc. | Iain D. Dukes | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 4,801 | 4,801 | - | - | Series C Preferred Stock | |
| Traws Pharma Inc. | Iain D. Dukes | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 194 | 194 | - | - | Series C Preferred Stock | |
| Iovance Biotherapeutics Inc | Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 100,000 | 100,000 | - | - | Deferred Restricted Stock Unit | |
| Iovance Biotherapeutics Inc | D. Dukes Iain | Director | Purchase of securities on an exchange or from another person at price $ 9.15 per share. | 20 Feb 2024 | 32,000 | 54,000 (0%) | 0% | 9.2 | 292,800 | Common Stock |
| Theseus Pharmaceuticals Inc | Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,500 | 19,500 | - | - | Stock Option (right to buy) | |
| Theseus Pharmaceuticals Inc | Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 3,250 | 3,250 | - | - | Restricted Stock Unit | |
| Ikena Oncology Inc | Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 17,520 | 17,520 | - | - | Stock Option (Right to Buy) | |
| Iovance Biotherapeutics Inc | Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 103,911 | 103,911 | - | - | Deferred Restricted Stock Unit | |
| Iovance Biotherapeutics Inc | Iain D. Dukes | Director | Purchase of securities on an exchange or from another person at price $ 6.10 per share. | 23 Nov 2022 | 10,000 | 22,000 (0%) | 0% | 6.1 | 61,000 | Common Stock |
| Iovance Biotherapeutics Inc | Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 102,409 | 102,409 | - | - | Deferred Restricted Stock Unit | |
| Theseus Pharmaceuticals Inc | Iain D. Dukes | Director, Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Theseus Pharmaceuticals Inc | Iain D. Dukes | Director, Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Ikena Oncology Inc | Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 13,419 | 13,419 | - | - | Stock Option (Right to Buy) | |
| Ikena Oncology Inc | Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 23,419 | 23,419 | - | - | Stock Option (Right to Buy) | |
| Theseus Pharmaceuticals Inc | Iain D. Dukes | Director, Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2021 | 22,678 | 22,678 | - | - | Stock Option (right to buy) | |
| Iovance Biotherapeutics Inc | Iain D. Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Iovance Biotherapeutics Inc | Iain Dukes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 70,000 | 70,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges